St. Jude's Research Children's Hospital
The roots of pediatric cancer are hidden deep within a child’s DNA. The St. Jude—Washington University Pediatric Cancer Genome Project is the world’s most ambitious effort to discover the origins of childhood cancer and seek new cures. By comparing the complete genomes from cancerous and normal cells for more than 800 patients, we have successfully pinpointed the genetic factors behind some of the toughest pediatric cancers. We are now using multiple approaches to analyze cancer genomes even more deeply. We are also developing a state-of-the-art clinical genomics program to better diagnose and treat children with cancer.
Arnold Palmer Hospital for Children
The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) is a group of 25 universities and children’s hospitals headquartered at the Helen Devos Children’s Hospital that offer a nationwide network of childhood cancer clinical trials. These trials are based on the research from a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk neuroblastoma and medulloblastoma.
Our mission is to create a national collaborative effort of researchers, oncologists and family advocates to bring forward new therapies for children with relapsed neuroblastoma and medulloblastoma with the goal of improving the quality of life and survival of children with neuroblastoma and medulloblastoma.
St. Baldrick's Foundation St. Baldrick’s donations helped fund research that has resulted in the first successful immunotherapy treatment for a childhood cancer, high-risk neuroblastoma. Neuroblastoma is a cancer of the sympathetic nervous system. The average age of diagnosis is 2, and it’s rare in children over 10 years old. Most patients have the high-risk form of the disease, and for years, only 1 in 3 of these children survived. With this new treatment, almost half may survive! The treatment, developed by Dr. Alice Yu, a St. Baldrick’s researcher at the University of California San Diego, tested the effects of immunotherapy on the relapse rate of neuroblastoma patients. Immunotherapy boosts the immune system to attack cancer cells by introducing man-made agents, like an antibody, to fight off the cancer. In the case of neuroblastoma, Dr. Yu and her team of researchers introduced an antibody called CH14.18, which targets a molecule on the surface of tumor cells called GD2.
Children's Hospital of Philadelphia CHOP researchers are launching a pediatric clinical trial with a dynamic design allowing them to quickly incorporate new treatments based on ongoing lab studies of evolving genetic changes in an individual patient’s tumor. The researchers will match those gene changes with available drugs. Research-based treatment of neuroblastoma, an-often lethal childhood cancer that remains difficult to cure. Usually appearing as a solid tumor in the chest or abdomen, neuroblastoma accounts for a disproportionate share of cancer deaths in children, despite many recent improvements in therapy.